CCL11 (C-C Motif Chemokine Ligand 11)

Our findings unveil CCL11 as a master regulator of the pro-tumorigenic niche post-resection, driving recurrence through coordinated immune evasion and promoting tumor invasiveness. Targeting the CCL11-CCR5/CCR3 axis presents a promising strategy to improve HCC surgical outcomes.

LIFI demonstrated strong discrimination (C statistic, 0.83) and was associated with post-LT infections, longer hospital stays, and reduced patient survival. Per the results of this diagnostic/prognostic study, LIFI identifies LT candidates with severe immune dysfunction at high risk for early post-LT mortality, offering a preoperative, objective tool to refine transplant candidacy, guide perioperative management, and improve LT outcomes.

Conversely, CCL11 overexpression promotes malignant cellular behavior, but these effects can be reversed by aspartate through inhibition of NF-κB and MAPK signaling pathways. This study elucidates a genetic variant-driven "metabolism-inflammation" carcinogenic pathway, providing novel insights into the mechanisms of oral cancer development and demonstrating significant translational potential for precision prevention and precision therapy.

Our findings reveal differential toxicological and chemical profiles for nicotine and 6-MN aerosols; however, flavorings may confer similar cytotoxicity, as measured by LDH and metabolic activity, in 6-MN formulations as they do in those with nicotine. Thus, 6-MN is not a "safer" nicotine alternative.

P=N/A, N=20, Active, not recruiting, Queen's University | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Jan 2026

Our results lend support to the presumption that inflammatory cytokines are important biomarkers that associate with DR severity and may represent novel targets for inhibition. The authors have no proprietary or commercial interest in any materials discussed in this article.

This review outlines emerging circulating, tissue-derived and imaging biomarker candidates in VS that may complement MRI and support more precise diagnosis, monitoring, and individualized management.

P=N/A, N=70, Completed, University Hospital, Lille | Unknown status --> Completed

Lenvatinib treatment has broad immunomodulatory effects in patients with TC, including shifts in immune cell populations, changes in the proteome, and reprogramming of cytokine responses. Lenvatinib also impacts monocyte metabolism and tumor cell phenotype. These findings provide insight into the multifaceted immunological activities of lenvatinib and highlight opportunities for treatment strategies.

The antagonistic activity of that specific antagonist of TLR4 (TAK-242) (1 µmol·L-1), a specific TLR4 blocker, against S1 (10 µmol·L-1) was examined in co-cultured 16HBE cells and bone marrow-derived cells (BMDCs) or splenic lymphocytes (SLs) induced with LPS (1 µg·mL-1) to elucidate the TLR4 pathway's mediating role...S1's therapeutic effects occur through regulation of Th17/Treg immune cells and inflammation, attributable at least partially to the TLR4 pathway. This study provides molecular justification for S1 in AA treatment.

We developed a predictive model for vascular issues in LIHC, identified important gene ITGA11 that can promote angiogenesis in LIHC and influence tumor progression in LIHC patients through the regulation of angiogenesis. We also found a small molecule medication called diosgenin that can target ITGA11's angiogenic effects.

P=N/A, N=66, Recruiting, Amsterdam UMC, location VUmc